Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Radioimmunotherapy (Y-90 M5A) in Combination With FOLFIRI and Bevacizumab Chemotherapy for Metastatic Colorectal Carcinoma

NCT01205022 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT01205022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01205022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Radioimmunotherapy (Y-90 M5A) in Combination With FOLFIRI and Bevacizumab Chemotherapy for Metastatic Colorectal Carcinoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2011
Completion date
January 31, 2014
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent colon cancer, recurrent rectal cancer, stage iv colon cancer, stage iv rectal cancer